Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 76.3%

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 183,974 shares, a growth of 76.3% from the June 30th total of 104,336 shares. Based on an average daily volume of 2,270,132 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.6% of the company’s shares are short sold.

VYNE Therapeutics Trading Down 0.8%

Shares of VYNE stock opened at $28.32 on Friday. The company has a market cap of $18.98 million, a P/E ratio of -74.54 and a beta of 2.00. The firm has a fifty day moving average price of $33.60 and a 200 day moving average price of $31.47. VYNE Therapeutics has a 12 month low of $14.03 and a 12 month high of $79.75.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings results on Friday, May 15th. The company reported ($4.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($9.00) by $5.00. The company had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.

VYNE Therapeutics Announces Dividend

The firm also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were issued a $19.00 dividend.

Institutional Investors Weigh In On VYNE Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Rangeley Capital LLC boosted its stake in shares of VYNE Therapeutics by 18.1% during the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock worth $71,000 after acquiring an additional 18,064 shares in the last quarter. XTX Topco Ltd purchased a new position in VYNE Therapeutics in the 4th quarter valued at approximately $46,000. Geode Capital Management LLC increased its stake in VYNE Therapeutics by 64.2% in the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after purchasing an additional 88,030 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in VYNE Therapeutics during the second quarter worth $176,000. Finally, Jane Street Group LLC acquired a new position in VYNE Therapeutics during the second quarter worth $206,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.